Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Immunophenotypic response

Outcome Description:

Response will be measured by International Myeloma Working Group (IMWG) guidelines, and if the response is stringent CR and immunophenotypic remission, those patients will be followed also by allele-spesific oligonucleotide-polymerase chain reaction assay (ASO-PCR) to find out molecular remission rate.

Outcome Time Frame:

Change from the start of induction treatment at 3 months, change from the start of induction at 6 months, at 9 months, at 12 months, at 16 months, at 20 months, at 24 moths

Safety Issue:

Yes

Authority:

Finland: Finnish Medicines Agency

Study ID:

KUH5101424

NCT ID:

NCT01790737

Start Date:

January 2013

Completion Date:

December 2017

Related Keywords:

• Multiple Myeloma
• myeloma, stem cell mobilization, autologous stem cell transplantation
• induction treatment, maintenance treatment
• Multiple Myeloma
• Neoplasms, Plasma Cell